Yes. At-home Leqembi still requires MRI monitoring for Alzheimer’s patients because home administration changes where the medicine is injected, not the risk of amyloid-related imaging abnormalities, or ARIA. A patient using the Leqembi IQLIK autoinjector may avoid many infusion-center visits, but still needs a baseline brain MRI and scheduled follow-up scans. For example, current dosing guidance calls for an MRI after the first month of treatment—before the third IV dose or the fifth weekly subcutaneous dose.
The MRI schedule applies whether treatment begins with intravenous Leqembi or once-weekly subcutaneous Leqembi IQLIK. Current prescribing materials call for imaging at baseline and after months 1, 2, 3, and 6, generally within about one week before the next dose and reviewed before treatment proceeds. Additional scans may be necessary whenever symptoms or earlier images raise concern for ARIA. The FDA approved Leqembi IQLIK for at-home initiation in July 2026, although the manufacturer expects the starting-dose product to become available in the United States in late August 2026. The new option reduces treatment travel, but patients remain under medical supervision and must continue safety testing, neurological follow-up, and medication review.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Does At-Home Leqembi Still Require MRI Monitoring for Alzheimer’s Patients?
- Why MRI Monitoring Remains Necessary With Leqembi IQLIK
- ARIA Risk, APOE ε4 Status, and Baseline Imaging
- Planning MRI Visits Around At-Home Leqembi Doses
- Symptoms, Blood Thinners, and Emergency Care
- What Happens When an MRI Shows ARIA?
- Switching From Infusions to At-Home Maintenance
- Frequently Asked Questions
Does At-Home Leqembi Still Require MRI Monitoring for Alzheimer’s Patients?
At-home leqembi requires MRI monitoring because lecanemab can cause ARIA-E, involving brain swelling or fluid accumulation, and ARIA-H, involving small areas of bleeding or iron deposits. Many ARIA cases cause no noticeable symptoms and are discovered only on an MRI. A person may feel entirely normal while a scheduled scan shows changes significant enough to pause treatment. According to the current Leqembi dosing guidance, patients need a recent baseline brain MRI before treatment and monitoring scans after months 1, 2, 3, and 6.
The timing is based on the duration of treatment rather than the delivery method. The first follow-up scan therefore falls before the third dose of medication given every two weeks by IV, but before the fifth dose when medication is injected weekly. At-home administration should not be confused with at-home medical management. The autoinjector can move dosing out of an infusion center, but an imaging facility must still perform the MRI, and the prescribing clinician must review it. If a required scan is missed or has not been reviewed, the family should contact the treatment team before administering the next scheduled dose.
Why MRI Monitoring Remains Necessary With Leqembi IQLIK
Leqembi targets aggregated forms of amyloid beta in the brain. Removing amyloid can affect blood vessels already made fragile by amyloid deposits, producing swelling or bleeding that is visible on MRI. The FDA's at-home Leqembi announcement notes that ARIA is often asymptomatic but can occasionally produce serious or life-threatening neurological problems. An MRI can detect edema, small hemorrhages, and superficial siderosis more effectively than a routine head CT.
A CT may be used during an emergency to assess major bleeding or another urgent problem, but it is not a substitute for the scheduled MRI protocol. This is an important limitation for people who have severe claustrophobia, cannot lie still, or have an implanted device that may not be MRI-compatible. Monitoring also does not stop automatically after the scheduled early scans. The clinician may order an unscheduled MRI for a new headache, confusion, visual change, dizziness, nausea, balance difficulty, weakness, speech trouble, or seizure. Families should not wait for the next routine appointment when a new neurological symptom develops.
ARIA Risk, APOE ε4 Status, and Baseline Imaging
Before Leqembi is started, the baseline MRI helps identify existing microhemorrhages, superficial siderosis, prior major bleeding, or other findings associated with cerebral amyloid angiopathy. These abnormalities can raise the risk of ARIA or intracerebral hemorrhage. In the pivotal clinical trial, people with more than four microhemorrhages or certain other high-risk imaging findings were excluded, so safety evidence is more limited for patients with those features. APOE ε4 genetic status also matters.
People with two copies of the APOE ε4 variant have a higher incidence of ARIA, including symptomatic and severe cases, than people with one copy or no copies. Current prescribing information says APOE ε4 testing should be performed before treatment to inform the risk discussion, although a patient may still be treated without testing if the uncertainty is understood. For example, two patients with the same mild cognitive impairment diagnosis may face different decisions if one is an APOE ε4 homozygote with two baseline microbleeds and the other is a noncarrier with an unremarkable MRI. Both follow the scheduled imaging protocol, but the first patient may need a more cautious benefit-risk discussion and a lower threshold for additional scans.
Planning MRI Visits Around At-Home Leqembi Doses
Patients and caregivers should obtain a written calendar showing injection dates, MRI dates, and neurology appointments. The scheduled MRI is generally performed within approximately one week before the relevant injection or infusion and should be reviewed before that dose proceeds. Scheduling the scan is only part of the task; the treatment team also needs enough time to receive and interpret the images. The practical tradeoff is fewer infusion-center visits in exchange for responsibility at home. During the first 18 months, Leqembi IQLIK initiation uses 500 mg once weekly, delivered as two sequential 250 mg injections.
After 18 months, the subcutaneous maintenance regimen is 360 mg once weekly using one autoinjector. IV treatment instead requires an infusion about every two weeks during initiation, with less frequent IV maintenance available after 18 months. Current instructions also require a healthcare professional to provide guidance and supervision for at least two consecutive subcutaneous doses before deciding that the patient or caregiver can administer the medicine appropriately. Cognitive changes, impaired vision, tremor, or difficulty remembering steps may make caregiver administration safer than self-injection. The clinician should periodically reassess that ability rather than assuming it will remain unchanged.
Symptoms, Blood Thinners, and Emergency Care
New neurological symptoms during Leqembi treatment require prompt attention even when the medication is administered at home. Warning signs include severe or persistent headache, sudden confusion, visual disturbance, dizziness, nausea, trouble walking, weakness, numbness, speech difficulty, or seizure. ARIA-E can resemble an ischemic stroke, creating a potentially dangerous diagnostic problem in the emergency department. Patients should tell emergency clinicians that they are receiving lecanemab before thrombolytic treatment is considered.
The FDA warns that serious brain hemorrhages, including fatal cases, have occurred with this class of medicines. A caregiver can help by keeping the medication name, prescriber’s number, most recent dose, and most recent MRI date in a wallet card or phone record. Anticoagulants and other medications affecting bleeding also require careful review. Starting a blood thinner after Leqembi has begun is not a routine medication change; the neurologist and the clinician treating the clotting or heart condition should evaluate the competing risks. Aspirin, anticoagulants, and emergency clot-dissolving drugs are not interchangeable, and a family should never stop a prescribed cardiovascular medicine without medical direction.
What Happens When an MRI Shows ARIA?
An abnormal MRI does not produce one automatic decision. Management depends on whether the patient has symptoms, whether the finding is ARIA-E or ARIA-H, and whether imaging severity is mild, moderate, or severe.
A clinician may continue treatment in selected mild cases, suspend doses, arrange follow-up imaging, or permanently discontinue Leqembi when the risk is unacceptable. For example, mild asymptomatic ARIA-E may sometimes be monitored while dosing continues under clinical judgment, whereas moderate or severe ARIA generally leads to treatment suspension. Follow-up MRI is used to determine whether swelling has resolved or bleeding findings have stabilized before treatment is resumed; feeling better alone is not enough to establish radiographic resolution.
Switching From Infusions to At-Home Maintenance
A patient switching to at-home Leqembi after 18 months of IV therapy does not ordinarily restart the early-treatment MRI calendar solely because the route changed. That patient should already have completed the routine early scans, but symptom-triggered imaging and individualized monitoring remain in effect. A history of ARIA may justify additional surveillance even during long-term maintenance.
During maintenance, patients may switch between IV and subcutaneous treatment under the prescribing schedule. The first weekly maintenance injection is generally given one week after the last maintenance dose of the previous route. Each autoinjector must be refrigerated as directed, inspected before use, allowed to reach room temperature for 20 minutes, and discarded in an appropriate sharps container after the injection.
Frequently Asked Questions
Can a patient skip an MRI if no ARIA symptoms are present?
No. Scheduled MRIs are intended partly to detect asymptomatic ARIA. Feeling well does not replace the baseline or required follow-up imaging.
Is MRI monitoring different for IV and at-home Leqembi?
The monitoring points are aligned by treatment month: baseline and after months 1, 2, 3, and 6. The corresponding dose number differs because IV treatment is given every two weeks while subcutaneous treatment is weekly.
Can a CT scan replace the scheduled MRI?
Generally, no. MRI is the specified monitoring method because it is better suited to identifying the swelling, microhemorrhages, and superficial siderosis associated with ARIA.
Does switching to Leqembi IQLIK after 18 months require another baseline MRI?
A new baseline MRI is not routinely required merely because the administration route changes. The clinician may still order imaging based on symptoms, previous ARIA, other medical changes, or the age and quality of available scans.
Who can administer at-home Leqembi?
A patient or caregiver may administer it after appropriate instruction. Current guidance calls for professional guidance and supervision during at least two consecutive subcutaneous doses and periodic reassessment of the person’s ability to administer it safely.
What should a caregiver do if neurological symptoms appear after an injection?
Seek prompt medical evaluation and identify Leqembi by name to the treating clinicians. Sudden weakness, speech trouble, seizure, severe confusion, or other stroke-like symptoms warrant emergency assessment.
